LEXEO Therapeutics Closes $100 Million Series B Financing

Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors

Proceeds to support continued preclinical pipeline development in rare cardiovascular diseases and the genetics of Alzheimer’s disease; clinical development of the company’s lead programs toward meaningful data catalysts

NEW YORK – Sept. 9, 2021 (GLOBE NEWSWIRE) – LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, today announced that it closed a $100 million Series B financing, led by D1 Capital Partners and Eventide Asset Management, and joined by CAM Capital, Verition Fund Management, Laurion Capital Management, Gray’s Creek Capital Partners, and existing investors Longitude Capital, Omega Funds, Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Woodline Partners LP, Invus Capital, and Alexandria Venture Investments.

Contact Us